Public School Adolescents Had Increased Odds of Being Willing to Uptake HPV Vaccinations Owing to Sociodemographic and Healthcare Access Features in Bahir Dar City, Ethiopia.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
08
2022
revised:
10
02
2023
accepted:
20
02
2023
medline:
25
4
2023
pubmed:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Cervical cancer is one of the most prevalent and fatal malignancies in women worldwide. Despite the fact that vaccination is an effective method in reducing cervical cancer, its uptake varies between public and private school adolescents and remains a challenge in low- and middle-income countries, including Ethiopia. Empirical evidence on how much variation there is among public and private school adolescent in their willingness to uptake human papillomavirus (HPV) vaccination is also limited. Thus, the aim of this study was to compare levels of willingness to uptake HPV vaccination among public and private school female adolescents and associated factors in Bahir Dar City, Ethiopia. A comparative cross-sectional study was conducted on 844 adolescents aged 10 to 19 in primary schools in Bahir Dar, Ethiopia. Multistage sampling was used. A self-administered, structured, and pretested questionnaire was used to collect data. The determinants of willingness to accept HPV vaccination were identified using logistic regression, and exploratory factor analyses were performed to determine load and mean. The level of statistical significance was determined using a The overall proportion of willing to uptake HPV vaccination was 50.6% (95% CI: 47.4-54), whereas in public and private primary schools, the magnitude was 61% (95% CI: 56.3-65.4%) and 40.2% (95% CI: 35.6-44.9), respectively. In terms of willingness to uptake HPV vaccination, the odds were likely to be significantly higher among those whose mothers had a postsecondary education (AOR = 2.0, 95% CI: 1.29-3.05), a high cue to action (AOR = 1.92, 95% CI: 1.20-3.05), and high self-efficacy (AOR = 2.34, 95% CI: 1.58-3.48). High perceived barriers likely decreased the willingness to uptake HPV vaccination (AOR = 0.49, 95% CI: 0.34-0.70). Adolescent girls in public primary schools were more likely to uptake HPV vaccination than those in private provided that income status and socioeconomic factors became less important. Willingness to uptake HPV vaccination was found to be low as compared to the WHO target for Ethiopian context and was influenced by maternal education status, perceived barriers, cues to action, and self-efficacy. As a result, greater emphasis should be placed on implementing a school-based and maternal educational program on cervical cancer prevention and control focusing on the behavioral contexts.
Sections du résumé
Background
UNASSIGNED
Cervical cancer is one of the most prevalent and fatal malignancies in women worldwide. Despite the fact that vaccination is an effective method in reducing cervical cancer, its uptake varies between public and private school adolescents and remains a challenge in low- and middle-income countries, including Ethiopia. Empirical evidence on how much variation there is among public and private school adolescent in their willingness to uptake human papillomavirus (HPV) vaccination is also limited. Thus, the aim of this study was to compare levels of willingness to uptake HPV vaccination among public and private school female adolescents and associated factors in Bahir Dar City, Ethiopia.
Methods
UNASSIGNED
A comparative cross-sectional study was conducted on 844 adolescents aged 10 to 19 in primary schools in Bahir Dar, Ethiopia. Multistage sampling was used. A self-administered, structured, and pretested questionnaire was used to collect data. The determinants of willingness to accept HPV vaccination were identified using logistic regression, and exploratory factor analyses were performed to determine load and mean. The level of statistical significance was determined using a
Results
UNASSIGNED
The overall proportion of willing to uptake HPV vaccination was 50.6% (95% CI: 47.4-54), whereas in public and private primary schools, the magnitude was 61% (95% CI: 56.3-65.4%) and 40.2% (95% CI: 35.6-44.9), respectively. In terms of willingness to uptake HPV vaccination, the odds were likely to be significantly higher among those whose mothers had a postsecondary education (AOR = 2.0, 95% CI: 1.29-3.05), a high cue to action (AOR = 1.92, 95% CI: 1.20-3.05), and high self-efficacy (AOR = 2.34, 95% CI: 1.58-3.48). High perceived barriers likely decreased the willingness to uptake HPV vaccination (AOR = 0.49, 95% CI: 0.34-0.70).
Conclusion
UNASSIGNED
Adolescent girls in public primary schools were more likely to uptake HPV vaccination than those in private provided that income status and socioeconomic factors became less important. Willingness to uptake HPV vaccination was found to be low as compared to the WHO target for Ethiopian context and was influenced by maternal education status, perceived barriers, cues to action, and self-efficacy. As a result, greater emphasis should be placed on implementing a school-based and maternal educational program on cervical cancer prevention and control focusing on the behavioral contexts.
Identifiants
pubmed: 37090189
doi: 10.1155/2023/2663815
pmc: PMC10115532
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2663815Informations de copyright
Copyright © 2023 Birhanu Feleke Shitu et al.
Déclaration de conflit d'intérêts
The authors declare that they had no competing interests.
Références
J Natl Cancer Inst. 2015 Apr 29;107(6):djv086
pubmed: 25925419
J Prev (2022). 2022 Apr;43(2):225-240
pubmed: 35286543
S Afr Med J. 2018 Dec 13;109(1):13-15
pubmed: 30606297
Hum Vaccin Immunother. 2021 Mar 4;17(3):828-835
pubmed: 32873128
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
Open AIDS J. 2016 Apr 08;10:34-48
pubmed: 27347270
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:42-58
pubmed: 28986092
J Adolesc Health. 2008 Oct;43(4 Suppl):S5-25, S25.e1-41
pubmed: 18809145
Hum Vaccin Immunother. 2022 Dec 31;18(1):2036522
pubmed: 35236252
Heliyon. 2021 May 17;7(5):e07051
pubmed: 34041397
Bull World Health Organ. 2019 Jan 01;97(1):42-50
pubmed: 30618464
Afr Health Sci. 2019 Dec;19(4):3009-3017
pubmed: 32127876
Skin Therapy Lett. 2006 Jul-Aug;11(6):1-3
pubmed: 16912836
J Clin Pathol. 2002 Apr;55(4):244-65
pubmed: 11919208
Vaccine. 2019 Feb 4;37(6):889-897
pubmed: 30638797
Vaccine. 2017 Oct 13;35(43):5753-5755
pubmed: 28596091
Tour Manag. 2022 Feb;88:104405
pubmed: 34456412
Hum Vaccin Immunother. 2014;10(9):2536-42
pubmed: 25483471
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Womens Health Issues. 2022 May-Jun;32(3):293-300
pubmed: 34802859
Papillomavirus Res. 2020 Dec;10:100204
pubmed: 32750429
BMC Infect Dis. 2017 May 16;17(1):346
pubmed: 28511636
Psychol Health Med. 2015;20(2):239-46
pubmed: 24862090
Vaccines (Basel). 2020 Jan 16;8(1):
pubmed: 31963370
J Adolesc Health. 2017 Feb;60(2):204-211
pubmed: 27939879
Trop Med Infect Dis. 2020 Apr 09;5(2):
pubmed: 32283644
BMC Infect Dis. 2011 Jan 12;11:13
pubmed: 21226933
Infect Drug Resist. 2022 Mar 03;15:781-793
pubmed: 35264861
Afr J AIDS Res. 2015;14(3):209-18
pubmed: 26284910
Reprod Health. 2022 Jun 10;19(1):136
pubmed: 35689288
Front Public Health. 2022 May 24;10:860809
pubmed: 35685759
Cancer Manag Res. 2020 Sep 16;12:8519-8526
pubmed: 32982444
Vaccine. 2010 May 14;28(22):3809-17
pubmed: 20347631
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Front Public Health. 2021 Feb 19;9:598625
pubmed: 33681125
PLoS One. 2020 Apr 30;15(4):e0231459
pubmed: 32352983
J Trop Med. 2017;2017:8586459
pubmed: 29410683